  |
Lægemiddelstofklassifikation ATC |
M | ||
 |
Antineoplastiske og immunomodulerende midler |
ML | ||
 |
antineoplastiske stoffer |
ML01 | ||
|
monoklonale antistoffer og antistof-lægemiddel-konjugater |
ML01F | ||
 |
andre monoklonale antistoffer og antistof-lægemiddel-konjugater |
ML01FX | ||
 |
edrecolomab |
ML01FX01 | ||
|
gemtuzumab ozogamicin |
ML01FX02 | ||
|
catumaxomab |
ML01FX03 | ||
|
ipilimumab |
ML01FX04 | ||
|
brentuximab vedotin |
ML01FX05 | ||
|
dinutuximab beta |
ML01FX06 | ||
|
blinatumomab |
ML01FX07 | ||
|
elotuzumab |
ML01FX08 | ||
|
mogamulizumab |
ML01FX09 | ||
|
olaratumab |
ML01FX10 | ||
|
bermekimab |
ML01FX11 | ||
|
tafasitamab |
ML01FX12 | ||
|
enfortumab vedotin |
ML01FX13 | ||
|
polatuzumab vedotin |
ML01FX14 | ||
|
belantamab mafodotin |
ML01FX15 | ||
|
oportuzumab monatox |
ML01FX16 | ||
|
sacituzumab govitecan |
ML01FX17 | ||
|
amivantamab |
ML01FX18 | ||
|
sabatolimab |
ML01FX19 | ||
|
tremelimumab |
ML01FX20 | ||
|
naxitamab |
ML01FX21 | ||
|
loncastuximab tesirin |
ML01FX22 | ||
|
tisotumab vedotin |
ML01FX23 | ||
|
teclistamab |
ML01FX24 | ||
|
mosunetuzumab |
ML01FX25 | ||
|
mirvetuximab soravtansin |
ML01FX26 | ||
|
epcoritamab |
ML01FX27 | ||
|
glofitamab |
ML01FX28 | ||
|
talquetamab |
ML01FX29 | ||
|
zolbetuximab |
ML01FX31 | ||
|
elranatamab |
ML01FX32 | ||
|
tarlatamab |
ML01FX33 | ||
 |
odronextamab |
ML01FX34 |
TEXT